Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Lapatinib Plus Myocet TM in Patients With HER2+ve Metastatic Breast Cancer Following Disease Progression During, or After, Treatment With Trastuzumab and Taxanes

NCT01495884 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT01495884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01495884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Lapatinib Plus Myocet TM in Patients With HER2+ve Metastatic Breast Cancer Following Disease Progression During, or After, Treatment With Trastuzumab and Taxanes
Lead sponsor
Cancer Trials Ireland
Phase
Phase 1/2
Overall status
Terminated
Start date
March 31, 2011
Completion date
October 31, 2014
Enrollment
11 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

her2 positive metastatic breast cancer